Using genetically engineered murine models to study TP53/KRAS-driven lung cancer, researchers showed the effectiveness of combining MEK inhibitor with either anti-PD-1 or anti-PD-L1 in increasing anti-tumour immune responses and improving survival of lung cancer bearing mice. Here, MAP2K7 is linked to lung carcinoma.